Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

D.A.Y. MEDICAL CONSULTING ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 0.7% 0.7%   Bankruptcy risk   2.2% 2.6% 2.0% 2.6% 4.5% 6.9% 17.6% 17.6%   Credit score (0-100)   68 63 69 60 46 34 9 9   Credit rating   BBB BBB A BBB BBB BBB B B   Credit limit (kDKK)   0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   492 307 475 338 86.8 248 0.0 0.0   EBITDA   492 307 475 338 86.8 248 0.0 0.0   EBIT   492 127 278 141 -110 34.5 0.0 0.0   Pre-tax profit (PTP)   486.0 123.4 263.7 102.4 -158.2 32.0 0.0 0.0   Net earnings   380.3 96.5 199.0 77.1 -123.4 24.9 0.0 0.0   Pre-tax profit without non-rec. items   486 123 264 102 -158 32.0 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   667 763 882 846 473 380 79.9 79.9   Interest-bearing liabilities   116 6.8 642 675 767 401 0.0 0.0   Balance sheet total (assets)   1,029 1,017 1,800 1,708 1,332 858 79.9 79.9   Net Debt   28.1 -205 -508 -569 -264 -365 -79.9 -79.9     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   492 307 475 338 86.8 248 0.0 0.0   Gross profit growth   2.8% -37.7% 54.9% -28.8% -74.3% 186.2% -100.0% 0.0%   Employees   0 0 0 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   1,029 1,017 1,800 1,708 1,332 858 80 80   Balance sheet change%   86.2% -1.2% 77.1% -5.1% -22.0% -35.6% -90.7% 0.0%   Added value   491.9 306.7 474.9 337.9 86.8 248.4 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   415 -276 -394 -394 -394 -428 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 -1.0 1.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   100.0% 41.3% 58.5% 41.7% -126.9% 13.9% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   62.2% 12.4% 19.7% 8.0% -7.2% 3.2% 0.0% 0.0%   ROI %   65.6% 13.1% 21.3% 8.6% -7.6% 3.4% 0.0% 0.0%   ROE %   79.8% 13.5% 24.2% 8.9% -18.7% 5.9% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   64.8% 75.1% 49.0% 49.5% 35.5% 44.3% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   5.7% -66.9% -107.0% -168.5% -303.6% -146.9% 0.0% 0.0%   Gearing %   17.4% 0.9% 72.8% 79.8% 162.2% 105.5% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   4.8% 5.2% 4.4% 5.8% 6.7% 0.6% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   0.8 2.8 1.5 1.7 1.4 1.8 0.0 0.0   Current Ratio   0.8 2.8 1.5 1.7 1.4 1.8 0.0 0.0   Cash and cash equivalent   88.2 212.0 1,150.3 1,244.4 1,030.5 765.7 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   -35.6 135.4 408.0 525.7 306.0 379.9 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0